Epigenetic biomarkers in skin cancer
详细信息 查看全文
- 作者：Edward S. Greenberg ; Kelly K. Chong ; Kelly T. Huynh ; Ryo Tanaka ; Dave S.B. Hoon
- 关键词：BC ; biochemotherapy ; BCC ; basal cell carcinoma ; BM ; biomarker ; SBM ; sodium bisulfite modification ; CAE ; capillary array electrophoresis ; cf-CNA ; cell-free circulating nucleic acid ; ChIP ; chromatin immunoprecipitation ; CIMP ; CpG island methylator phenotype ; CoBRA ; combined bisulfite restriction analysis ; CTC ; circulating tumor cell ; CTCL ; cutaneous T-cell lymphoma ; DNMT ; DNA methyltransferase ; IHC ; immunohistochemistry ; LINE-1 ; long interspersed nuclear element-1 ; MCC ; merkel cell carcinoma ; MINT
- 刊名：Cancer Letters
- 出版年：28 January, 2014
- 年：2014
- 卷：342
- 期：2
- 页码：170-177
- 全文大小：819 K
文摘
Epigenetic aberrations have been associated with cutaneous melanoma tumorigenesis and progression including dysregulated DNA gene promoter region methylation, histone modification, and microRNA. Several of these major epigenetic aberrations have been developed into biomarkers. Epigenetic biomarkers can be detected in tissue and in blood as circulating DNA in melanoma patients. There is strong evidence that biomarkers in cutaneous melanoma will have an important role as companions to therapeutics and overall patient management. Important progress has been made in epigenetic melanoma biomarker development and verification of clinical utility, and this review discusses some of the key current developments and existing challenges.